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SUMMARY
Health status measures in rheumatoid arthritis that have been extensively validated for use in clinical trials are generally used 
also in correlative studies, e.g. to predict future health status. This application requires stability (repeatability of measurements). 
The purpose of our study was to determine the stability of commonly used health status measures. Two measurements at an 
interval of 6 months were taken in 99 patients. High stability (a = 0.78 to 0.94) was observed for five biomedical measures (grip 
strength, walking time, platelet count, haemoglobin and erythrocyte sedimentation rate) and five self-report measures (mobility, 
self care, impact daily activities, anxiety and cheerful mood). Moderate stability (a = 0.65 to 0.72) was observed for joint scores, 
pain, C-reactive protein and depressive mood. The highly stable measures most adequately reflect individual differences, may 
be applied most reliably in correlative studies and appear to have the largest clinical utility with regard to long-term prediction 
of health status.
K ey w o r d s: Rheumatoid arthritis, Stability, Reliability, Validity, Outcome measures, Clinimetrics.
In rheumatoid arthritis (RA) health status measure­
ment for the purpose of therapy evaluation has been 
the subject of extensive research and has been validated 
in several ways [1,2]. Recently, recommendations on 
the use of process and outcome measures [3], defini­
tions of clinically important changes in patients and 
groups [4] and a core set of disease activity measures 
in clinical trials o f RA patients have been published [5].
The same measures that have been validated for the 
purpose of evaluation are generally used also in correl­
ative studies, examining whether health status variables 
predict future health status or vary concomitantly with 
other variables (e.g. demographic, biological or social 
variables). However, in correlative studies other con­
siderations should guide the choice of variables than 
those used in evaluation studies. In evaluation studies 
the ability of a measure to detect intra-individual 
change in response to treatment is important. Variance 
due to change, the responsiveness coefficient, reflects 
this property [6]. In correlative studies the ability of 
a measure to discriminate between individuals is 
important. Discrimination refers to variation between 
individuals. This property is reflected in the stability 
coefficient and other reliability coefficients [6], Stability
s to the extent to which measurements are the 
same when retested after some period of time. Stability 
is determined by: (a) repeatability (or changeability) 
of measurements and (b) the range of inter-individual 
differences. When variation between individuals is 
small then even minor intra-individual changes in 
health status may reduce stability. But when individual
i
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differences are large then even clinically relevant intra­
individual changes may only marginally affect the 
relative position of patients towards each other, and 
stability will be high.
Stability has hardly been investigated systematically 
[7] or only for very short intervals between measure­
ments [8-10]. A single measurement of health status 
reflects first of all enduring differences between indi­
viduals, i.e. the irreversible outcome of the disease and 
other stable aspects of individuals such as consti­
tutional differences. But a single assessment also 
reflects current disease activity and other temporary 
fluctuations such as seasonal variations and inaccuracy 
of measurements [7]. Whatever the cause of low 
stability, fluctuations of the disease or measurement 
error, if a health status measure predominantly reflects 
a transient state, little can be expected when 
measure is correlated with enduring aspects of persons 
or when it is used to predict future health status. The 
first and most important purpose of stability analysis 
is to quantify the extent to which health status 
measures in RA reflect stable individual differences.
In correlative studies conclusions are often based 
on single measurements, based on the assumption 
that these assessments reflect to a large extent stable 
individual differences between patients. Except for pain 
assessment [11], validation of this current practice to 
infer from periodic single assessments has not gained 
much attention. The second purpose of 
analysis is to determine whether it is meaningful to 
infer from a single assessment, e.g. to predict future 
health status.
If a single assessment of a variable proves to be 
unsuitable for prediction purposes, one could use: 
(a) composite measures of multiple variables or (b) the 
mean of repeated measurements of the same variable
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[11-13]. The mean of repeated measurements of a 
variable more accurately reflects relatively enduring 
characteristics of patients than does a single measure­
ment. This mean is consequently more appropriate to 
predict future health status. Stability analysis provides 
the tools to estimate the number o f measurements 
needed to arrive at a mean value that adequately 
reflects individual differences. This is the third purpose 
of stability analysis.
The aim of the present study was to quantify 
the stability of commonly used measures of health 
status in RA in order to validate their use in correlative
PATIENTS A N D  M ETHODS
Data were collected from 99 out-patients who 
regularly visited one o f four hospitals in the Utrecht 
area of The Netherlands. Selection criteria were: RA 
according to the 1987 classification criteria [14], a 
minimal age of 20 and a minimal disease duration of 
1 yr. Patients participated in a study on behavioural 
and occupational interventions or were on a waiting list 
[15]. In the current analysis data comprised two 
measurements collected after completion of the inter­
vention. The interval between these measurements was 
6 months. During these months on-going an­
tirheumatic drug therapies were continued. Biomedical 
measurements at the two time points were carried out 
by the same rheumatology research nurse; self-report 
questionnaires were collected on the same day. The 
characteristics of the patients are shown in Table I.
Two types of biomedical measures were taken:
TABLE I 
Characteristics o f the 99 patients
Gender (number of patients)
Female
Male
68
31
Age (yr)
*i
Mean (s.d .) 58 (12.7)
R a n ge 25 82
Disease duration (yr)
Mean (s,n.)
Range
14.8 (11.5) 
2 59
ARA functional class (number of patients)
I
II
1 "X1 *  * 
lb
III 10
IV 0
Medication* (number o f  patients)
NSAID or analgesic, no DM ARD 29
DMARD (HCQ/gold/pen/SASP/csp) 39
DMARD (methotrexate/azathioprine) 25
Prednisone alone 0
Complementary treatment alone 2
*IICQ, hydroxychloroquine; gold, aurothioglucose or auranoiin;
pen, D-pemeiiiamine; bAbr, sulphasaiazine; csp, cyclosporin. 
Patients using disease-modifying anti-rheumatic drugs (DMARDs) 
could also be using non-steroidal anti-inflammatory drugs
(NSAIDs). Nine of the patients using 
prednisone (2.5 15 mg/day) treatment. The 
patients was unknown.
were aiso on 
ation of four
clinical assessments and laboratory measures. Clinical 
assessments consisted of grip strength (patients were 
asked to squeeze the cuff of a partially inflated sphyg­
momanometer as tightly as possible; the mean value of 
the best grip strength of three attempts in the left and 
right hand was taken), Thompson joint score (clinical 
assessment of tender and swollen joints) [16] and 30-m 
walking time. Blood samples were analysed for 
erythrocyte sedimentation rate (ESR) (Westergren 
method), C-reactive protein (CRP; nephelometric), 
haemoglobin and platelet count (both by Coulter
counter).
To assess physical and psychosocial health status, 
the Impact of Rheumatic Diseases on General Health 
and Lifestyle (IRGL) self-report questionnaire was 
used [17]. This validated questionnaire is partly derived 
from the Arthritis Impact Measurement Scales 1 [18]. 
Of the seven scales used in the current analyses, three 
assess the physical dimension of health (mobility, self 
care and pain), three address psychological discomfort 
(anxiety, depressive mood and cheerful mood) and one 
scale assesses the impact of RA upon daily activities 
such as work, household activities and sleeping (impact 
daily activities).
Statistical analyses 
To estimate test-retest stability of measures Cron- 
bach’s a was computed using the SPSS procedure 
reliabilities [19]. This coefficient reflects the proportion 
of variance of the mean score of two measurements 
that is explained by stable individual differences. It can 
take any value between 0 and 1: a value approaching 
1 reflects a stable position of patients towards each 
other with two repeated measurements. The more 
repeated measurements are taken of a variable, the 
better the mean score of a patient reflects the usual 
position o f that patient relative to other patients. 
The Spearman-Brown formula was used to estimate 
stability coefficients of health status measures as a 
function of one to six theoretical measurements 
[8,20,21], in which the estimate of a single measure­
ment reflects the proportion of variance o f a single 
measurement (in the 6-month interval) that must be
ascribed to individual differences. estimated
stability coefficients show how many measurements are 
needed to arrive at a specific level of stability. As the 
required level of stability of a measure depends on 
the specific use of the measure, no s 
be considered adequate in all circumstances. For 
studies into groups of patients coefficients of 0.70 are 
considered sufficient; for clinical outcome studies 
with relatively few subjects or examining individual 
responses to treatment 0.90 may be a minimum [7, 13].
Lack of change in the test-retest interval as well 
as the range o f inter-individual differences determine 
stability estimates. To be able to interpret stability
the percentage of patients changing more 
than 36% relative to initial measurements was com­
puted for each variable. This 36% criterion has been
proposed to the cut-off of clinically
important change in individual patients [4].
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In all analyses missing values were deleted pair-wise. 
To meet requirements for parametric statistics 
transformations were applied where appropriate.
TABLE III
The estimated stability of health status measures as a function of the
number of measurements
Number of measurements
•  j -  —  -  -  •  -  ............................ ... 1
RESULTS
Stability
Descriptive statistics of the first of the two assess­
ments are shown in Table II. Estimates of stability 
coefficients as a function of one to six measurements 
are shown in Table III. Alpha coefficients are shown in 
column 2 of Table III. Overall, 65% (a =  0.65) to 94%
( a 0.94) of the observed score variances reflect stable
inter-individual differences. The proportion of variance 
in the group explained by individual differences is high
(a 0.78 to 0.94) in five biomedical measures (grip
strength, walking time, platelet count, haemoglobin 
and ESR) and five self-report measures (mobility, self 
care, anxiety, cheerful mood and impact daily activ­
ities). Moderate stability (a =  0.65 to 0.72) is observed 
for Thompson joint score, CRP, pain and depressive 
mood. Estimates of stability coefficients as a function 
of one to six measurements (columns 1-6 in Table III) 
show that with a single assessment the stability co­
efficients of more than half o f the measures, including 
all clinical observations and self-report measures of 
functional ability, are greater than 0.70; with three 
measurements all coefficients are in excess of 0.70.
1 2 3 4 5 6
Grip strength 0.89 I 0.94 0.96 0.97 0.98 0.98
Mobility 0.83 : 0.91 0.94 0.95 0.96 0.07
Self care 0.80 0.89 : 0.92 0.94 0.95 0.96
Anxiety 0.79 0.88 : 0.92 0.94 0.95 0.96
Walking time 0.77 0.87 : 0.91 0.93 0.94 0.95
Platelet count 0.74 0.85 0.89 : 0.92 0.93 0.94
Haemoglobin 0.72 0.84 0.89 : 0.91 0.93 0.94
Cheerful mood 0.72 0.84 0.89 : 0.91 0.93 0.94
Impact daily activities 0.71 0.83 0.88 : 0.91 0.92 0.94
ESR 0.64 : 0.78 0.84 0.88 : 0.90 0.91
Thompson joint score 0.56 : 0.72 0.79 0.84 0.87 0.89
Pain 0.56 : 0.72 0.79 0.84 0.87 0.88
C-reactive protein 0.52 0.68 : 0.76 0.81 0.84 0.86
Depressive mood 0.48 0.65 : 
•
0.74 0.79 0.82 0.85
The stability o f  two measurements over 6 months was computed 
using Cronbach’s a. This coefficient reflects the proportion of 
variance of the mean score of two measurements that is explained by 
stable individual differences. Coefficients of one measurement 
(reflecting the proportion of variance of scores of a single measure­
ment that must be ascribed to individual differences) and of three to 
six measurements were estimated with the Spearman-Brown for­
mula. From the Table it can be seen how many measurements are 
needed to arrive at a coefficient of, e.g., 0.70 or 0.90 (dotted lines; see 
text for the meaning of these levels). For instance 90% of the mean 
values of five repeated measurements of ESR reflect stable individual 
differences; the remaining 10% reflects ‘true’ changes in time (e.g. due 
to changes in disease activity) or measurement error.
Changeability 
Taking 36% intra-individual change from the first to 
the second measurement as a cut-off criterion for
clinically relevant change, it was proved that 70% of patients changed at the variables impact daily activities 
the patients changed at Thompson joint score, whereas (11 %), walking time (8%), platelet count (8%), anxiety 
the percentages for depressive mood and ESR were 56 (8%), mobility (4%), self care (3%) and haemoglobin 
and 54, respectively. Also, considerable proportions of (1%). These analyses show that a large part of the
the sample changed at CRP (43%), grip strength 
(34%), cheerful mood (29%) and pain (24%). Few
TABLE II
Descriptive statistics of health status measures of the 99 patients
Mean S.D. Range
Biomedical measures
Grip strength (mrnHg) 35 27 0 144
Walking time (s) 31 16 18 116
Platelet count (109/1) 287 91 55.549
Haemoglobin (mmol/1) 8.3 0.9 5.5-10.5
ESR (mm l slh) 34 28 3.140
Thompson joint score* 103 98 0 467
C-reactive protein (mg/1) 11 24 0 204
Self-report measures t
Mobility 19.0 6.3 7-28
Self care 24.4 6.0 10-32
Anxiety 18.8 6.0 10-32
Cheerful mood 10.8 4.8 0-24
Impact daily activities 22.0 5.1 10-35
Pain 15.6 4.5 6-25
Depressive mood 3.2 4.0 0-17
"■Theoretical range 0-534.
fScales of the IRGL. Theoretical ranges: mobility 7-28, self care 
8 -32, pain 6-25, anxiety 10-40, depressive mood 0--24, cheerful mood 
0-24, impact daily activities 10-40. A large impact of the disease is 
reflected in low scores for the scales mobility, self care and cheerful 
mood, and in high scores for the other scales.
sample shows a clinically relevant change between the 
two assessments and at least some variables. Intra­
individual changes are especially observed in joint 
scores, depressive mood, ESR, CRP, grip strength, 
cheerful mood and pain.
DISCUSSION
Although some variables perform better than others, 
most of the commonly used health status variables in 
RA largely reflect stable individual 
Table III may be used to guide the choice of variables 
in correlative studies and to decide whether a si 
measurement or the mean of repeated measurements is 
to be used.
In the current study the stability of measures of 
physical functioning (mobility, self care, walking time) 
reflects a lack of intra-individual change during the 
course of the study as well as inter-individual differ­
ences. This contrasts with measures that have been 
proven to be sensitive to change in clinical trials, e.g. 
ESR and joint scores [3, 5, 22]. In our study less than 
8% of the patients changed more than 36% at physical 
functioning, while more than half of the patients 
changed more than 36% at ESR and joint scores. These 
meaningful changes in a large proportion of the sample 
did not, however, affect stability to a large extent. This
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can on ly  mean that the stability of these variables must 
be explained in terms of individual differences. Due to 
this b ro ad  range of individual scores the relative posi­
tion o f  patients towards each other is maintained, even 
if a large part of the sample of patients shows clinical 
am elioration or deterioration while another part does
change. The observation of large heterogeneity 
in hea lth  status is in agreement with other studies
stability
Table III
assessment
in the first column of 
be used to decide whether a single
to predict future health status or to correlate 
more enduring characteristics of patients. The
estimates of five health 
measures do not exceed 0.70. Defining a value of 
70 a s  a relevant boundary, these five measures do 
provide a reliable characterization of health status
6-month interval of investigation. Whatever 
of this lower stability, whether it be real 
fluctuations in disease activity or inaccurate measure-
a single measurement of these less stable 
m easures reflects a more temporary and transient state 
o f  affairs. Therefore, correlations with enduring 
characteristics of patients or with future health status 
will very likely be low. Taking into account transient 
varia tion , the mean score o f repeated measurements 
o f  a less stable measure should be used to predict end
apply to early RA. It is conceivable that general health 
and well-being are more affected by inflammatory 
flares and remissions in patients with a recent dia­
gnosis, in whom there are less irreversible consequences 
of the disease, than in later phases of the disease [28]. 
The stability of measurements within these groups (and 
therefore, for example, the prediction of future health 
status) may vary accordingly.
Our study was designed before the American College 
of Rheumatology (ACR) and EULAR core sets of 
disease activity measures for RA clinical trials 
were established [1,5,29]. Nevertheless, most disease 
activity measures from these core sets were included 
in the current study, viz., a joint score, assessments 
of pain and physical function and the acute-phase 
reactants ESR and CRP. The choice of the ACR core 
set was guided by several validity considerations, 
especially sensitivity to change in clinical trials and the 
ability of measures to predict important long-term 
outcomes in RA. The extent to which the measures of 
the ACR core set comply with these two types of 
validity relates strongly to the stability of measures 
observed in this study. The moderately stable measures 
(joint scores, ESR and pain) are most sensitive to 
change in clinical trials, while the highly stable 
measures of physical function are the stronger predictors 
of long-term outcome in RA. The fact that certain 
variables were chosen in the core sets because of their
po in ts  rather than a single assessment. The mean of superior characteristics regarding therapy evaluation
to five measurements of joint scores, pain and does not mean that these variables are also superior
acute-phase reactants reflects individual differences as in predicting disease course or in correlative studies, 
adequately  as does a single assessment of-functional Values of grip strength, walking time, button test and
questionnaire scores of activities of daily living proved 
to have a substantial clinical utility regarding long-term 
prediction of health status, predicting morbidity and 
mortality 9 yr later [30]. By inference, it is worthwhile 
to study the long-term prediction of the other variables
repeatedly measured at the same moment. This may that proved to be stable in this study. Stability is an
.  .  ^  ^  * «  •  ■  ^  ^  1  1  i  t j i  i  j  1 i  1  1 _■
To be able to remove from the score both the 
variations that are due to inaccurate measurements and 
fluctuations of the disease, these measurements should
it several time points during the 6-month 
in terval. In the current study only grip strength was
have inflated the stability coefficient a little, because
true changes during the 6-month interval did
important feature of health status variables that should 
be considered next to (not opposed to) other generally
reduce the stability, whereas the reduction of stability recognized features such as sensitivity to change.
Stability should guide the choice of variables in cor­
relative studies and sensitivity to change in evaluation 
studies. The results of the current study therefore do
in o th e r  measurements was due to inaccurate measure-
seems rather representative for
a  *  m  Athe population of non-hospitalized patients with RA. not give rise to change the ACR preliminary core set
in com parison with other samples from the same area, of disease activity measures. Rather, it enhances our
the patients did not differ with respect to gender, age insight into the stability of distinct measures of the
or duration  o f the disease [17,23,24]. Moreover, the set, and consequently into the applicability of these
m eans and ranges of the measures evaluated do not measures in correlative investigations.
l l  ■ 4  ■ ■
from those found in other samples of 
out-patients" [7, 12, 16, 24 26]. Conclusions of the cur-
study apply to health status scores of patients
^  m >  i l  l T 7 .  J .  1 _
CONCLUSION
I
in  a
Stability should guide the choice of variables in
sh o rte r  time intervals stability obviously will be higher 
[9, 10]. Over a longer time course patients will show
differential clinical progression of the disease, result-
*  .m *  ***. f lü *  •«  >  ^  i  m _  A - ^
With correlative studies as sensitivity to change guides the
-  ,  -  .  - t  * r r n  .  1  *  1  •  j .
mg m  situ
a joint
more a
choice of variables in evaluation studies. The stability 
of commonly used health status measures in RA 
varies from moderate to high. The highly stable 
measures most adequately reflect individual differ- 
a ....... - ences. These highly stable measures may reliably
measure of functional be applied in correlative studies and appear to be
stability [27]. On a much longer time
varies between fixed limits
progress in some patients 
no t in others. The results of this study may not
term
health status.
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